Keyword Connections

ovarian cancer

Journals

30

1 PloS one

2 Asia-Pacific journal of oncology nursing

3 investigational new drugs

4 nanomedicine (london, england)

5 International journal of environmental research and public health

6 Environmental science & technology

7 International journal of cancer

8 health information and libraries journal

9 JAMA

10 the journal of pathology

11 blood advances

12 Cell reports

13 molecular & cellular proteomics : mcp

14 indian journal of medical ethics

15 Alternative therapies in health and medicine

16 Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)

17 cancer

18 Practical radiation oncology

19 gynecologic oncology

20 experimental and therapeutic medicine

21 Annals of oncology : official journal of the European Society for Medical Oncology

22 International journal of biological sciences

23 indonesian journal of biotechnology

24 american journal of perinatology

25 journal of gynecologic oncology

26 expert opinion on investigational drugs

27 cellular signalling

28 general physiology and biophysics

29 nature neuroscience

30 Journal of ovarian research

Research Groups

0

No Research Group Connected

Bibliographies

167

1 MicroRNA-21 as a biomarker for ovarian cancer detection

2 Risk of Endometriosis and Subsequent Ovary and Breast Cancers in Nurses: A Population-Based Cohort Study in Taiwan.

3 Defining the molecular evolution of extrauterine high grade serous carcinoma.

4 Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.

5 Current state and outlook for drug repositioning anticipated in the field of ovarian cancer.

6 ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.

7 A preliminary report: genistein attenuates cerebral ischemia injury in ovariectomized rats via regulation of the PI3K-Akt-mTOR pathway.

8 AS1411 aptamer-decorated cisplatin-loaded poly(lactic-co-glycolic acid) nanoparticles for targeted therapy of miR-21-inhibited ovarian cancer cells.

9 The Positive Fate of Biochar Addition to Soil in the Degradation of PHBV-Silver Nanoparticle Composites.

10 Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.

11 Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients.

12 GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.

13 TRIM59 Is a Novel Marker of Poor Prognosis and Promotes Malignant Progression of Ovarian Cancer by Inducing Annexin A2 Expression.

14 Increased temperature-related adeno-associated virus vectors transduction of ovarian cancer cells - essential signatures of AAV receptor and heat shock proteins.

15 Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein.

16 Metabolic Factors Contribute to T-cell Inhibition in the Ovarian Cancer Ascites.

17 Multicenter Experience with Neurally Adjusted Ventilatory Assist in Infants with Severe Bronchopulmonary Dysplasia.

18 RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.

19 Interferon-complement loop in transplant-associated thrombotic microangiopathy.

20 Phase 2 trial of montelukast for prevention of pain in sickle cell disease.

21 Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.

22 Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.

23 The American Board of Radiology Focused Practice Recognition in Brachytherapy (FPRB) Program: Opportunities lost, lessons learned, and future implications.

24 REALISE-ing their potential?: Implementing local library projects to support evidence-based health care.

25 Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.

26 roles of micrornas in ovarian cancer tumorigenesis: two decades later, what have we learned?

27 right place, right time: preferences of women with ovarian cancer for delivery of cam education

28 effect of zhenwu decoction combined with neoadjuvant chemotherapy on malignant characteristics of cancer cells in ovarian cancer

29 cáncer de ovario en el instituto nacional de oncología y radiobiología de cuba: 2001 a 2005 ovarian cancer at the national institute of oncology and radiobiology of cuba: 2001-2005

30 gene co-expression analyses differentiate networks associated with diverse cancers harbouring tp53 missense or null mutations

31 clinical significance of detecting cea, ca199, afp, hcg, ca153, ca125 in postoperative treatment of patients with ovarian cancer

32 case of ovarian cancer in a woman with undiagnosed graves’ disease: a case report and review of the literature

33 pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted ecoflex® nanoparticles for docetaxel delivery in ovarian cancer

34 evidence of differential effects of vitamin d receptor variants on epithelial ovarian cancer risk by predicted vitamin d status

35 utilization of wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas

36 ovarian cancer after in vitro fertilization

37 prawidłowa ciąża u pacjentki po operacji oszczędzającej płodność z powodu raka jajnika w stopniu ic i guza o granicznej złośliwości po stronie przeciwnej

38 natural killer cell-based immunotherapy in gynecologic malignancy: a review

39 avastin in clinical chemotherapy of malignant tumors

40 seldi-tof ms profiling of plasma proteins in ovarian cancer

41 altered expression pattern of topoisomerase iiα, in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy

42 effect of metformin on the prognosis of diabetic patients combined with gynecologic cancer: a meta-analysis

43 clinical and survival impact of fdg pet in patients with suspicion of recurrent ovarian cancer: a 6-year follow-up

44 overexpression of traf4 gene in ovarian cancer samples and association with metastasis and poor prognosis in patients

45 proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer

46 diagnosis, surgical treatment, and management of borderline ovarian surface epithelial neoplasms: report of 2 cases and review of literature

47 leptomeningeal carcinomatosis and bilateral internal auditory canal metastases from ovarian carcinoma

48 ocena wybranych parametrów klinicznych i biochemicznych u kobiet chorych na raka jajnika w okresie 5-letniej obserwacji

49 diagnostic and prognostic importance of venous thromboembolism in ovarian cancer

50 local renin angiotensin system in the reproductive system: a review of literature

51 centralization of ovarian cancer surgery: do patients benefit?

52 a case report of long term bevacizumab treatment in multiresistant ovarian cancer

53 estrogen biosynthesis and action in ovarian cancer

54 medical image of the week: bronchial clot removal via cryotherapy

55 cellular, molecular consequences of peroxisome proliferator- activated receptor-δ activation in ovarian cancer cells

56 brain metastasis in advanced serous borderline tumor of the ovary: a case presentation

57 hm015k, a novel silybin derivative, multi-targets metastatic ovarian cancer cells and is safe in zebrafish toxicity studies

58 comparative gene expression analysis of lymphocytes treated with exosomes derived from ovarian cancer and ovarian cysts

59 Coping Strategies among Malaysian Women with Recurrent Ovarian Cancer: A Qualitative Study.

60 Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers

61 Antigen presentation potential is variable among human ovarian tumour and syngeneic murine models and dictates pre-clinical outcomes of immunotherapy.

62 Fish intake and ovarian cancer risk: a meta-analysis of 15 case-control and cohort studies.

63 Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.

64 Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.

65 Insights into Impact of DNA Copy Number Alteration and Methylation on the Proteogenomic Landscape of Human Ovarian Cancer via a Multi-omics Integrative Analysis.

66 Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study.

67 Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study.

68 [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].

69 MicroRNA-936 targets FGF2 to inhibit epithelial ovarian cancer aggressiveness by deactivating the PI3K/Akt pathway.

70 Meeting report from the 2018 12th Biennial Ovarian Cancer Research Symposium detection and prevention of ovarian cancer.

71 Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts.

72 EGFR inhibition studies by hybrid scaffolds for their activity against ovarian cancer.

73 Phytochemicals in the treatment of ovarian cancer.

74 Patterns of ovarian cancer and uterine cancer mortality and incidence in the contiguous USA.

75 Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer

76 Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells

77 Discovery of HB-EGF binding peptides and their functional characterization in ovarian cancer cell lines

78 Prior uterine myoma and risk of ovarian cancer: a population-based case-control study.

79 Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.

80 Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.

81 [Medical treatment in ovarian cancers newly diagnosed: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

82 Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation.

83 Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer.

84 Peritoneal inflammation – A microenvironment for Epithelial Ovarian Cancer (EOC)

85 Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?

86 Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study

87 Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment.

88 Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR

89 Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells

90 NOS1 upregulates ABCG2 expression contributing to DDP chemoresistance in ovarian cancer cells

91 P-MAPA and IL-12 Differentially Regulate Proteins Associated with Ovarian Cancer Progression: A Proteomic Study.

92 Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.

93 A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles.

94 Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells.

95 microRNA-141-3p-containing small extracellular vesicles derived from epithelial ovarian cancer cells promote endothelial cell angiogenesis through activating the JAK/STAT3 and NF-κB signaling pathways.

96 Comment on “Circular RNAs and their emerging roles as diagnostic and prognostic biomarkers in ovarian cancer,” Cancer Lett. 2020 Jan 2; 473 (2020) 139-147

97 Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. Reply.

98 Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

99 Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

100 Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.

101 [Current advances in immunotherapy in ovarian cancer].